Smarter in Minutes #3: Paxlovid
Pre-Assessment

Before you view the activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit. There is no fee to participate in this activity.

Question Title

* 1. HCPs: What are your credentials?

ID MD/DO

PCP, FM, GP MD/DO

IM MD/DO

Geriatrician MD/DO

APP (NP or PA)

PharmD

Other (please specify)

Question Title

* 2. The EPIC-HR trial showed approximately what percentage relative risk reduction of hospitalization or all cause death through day 28 (≤3 days after symptom onset) following treatment with Paxlovid?

90%

70%

50%

40%

Question Title

* 3. Patients with moderate renal impairment (defined as eGFR ≥30 to <60 mL/min) can be given PAXLOVID as follows:

Not indicated in pts w/ renal impairment

Standard dose for 3 days

Standard dose for 5 days

Reduced dose for 5 days

Question Title

* 4. A white 60 yo male smoker with a BMI of 32 arrives at urgent care, complaining of severe cough for 3 days. His medical history includes hypertension, hypercholesterolnemia, and BPH. He received 2 COVID-19 vaccinations one year ago. Recently exposed by a co-worker. His PCR test is positive for SARS-COV-2 virus. What action should be taken?

Prescribe Paxlovid

Prescribe Remdesivir

Admit to observation unit @ hosp

Provide 02 by HFNC

Question Title

* 5. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).

First Name

Last Name

Degree/Credentials

State/Province

ZIP/Postal Code

Country

Email Address (required to receive credit)

Smarter in Minutes #3: Paxlovid***Pre-Assessment***

Question Title

* 1. HCPs: What are your credentials?

Question Title

* 2. The EPIC-HR trial showed approximately what percentage relative risk reduction of hospitalization or all cause death through day 28 (≤3 days after symptom onset) following treatment with Paxlovid?

Question Title

* 3. Patients with moderate renal impairment (defined as eGFR ≥30 to <60 mL/min) can be given PAXLOVID as follows:

Question Title

Question Title

* 5. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).

Smarter in Minutes #3: Paxlovid
Pre-Assessment